Ludlam H A, Barton I, White L, McMullin C, King A, Phillips I
Department of Microbiology, St. Thomas' Hospital, London, UK.
J Antimicrob Chemother. 1990 May;25(5):843-51. doi: 10.1093/jac/25.5.843.
Ciprofloxacin was evaluated as single-agent therapy for the empirical treatment of patients presenting with CAPD peritonitis in an open, uncontrolled trial. Seventy-five episodes of peritonitis in 44 patients receiving continuous ambulatory peritoneal dialysis were entered in the study. The antibiotic was administered intraperitoneally, at a dose of 50 mg/l in each bag of dialysate, for seven days. Treatment with ciprofloxacin was appropriate (organisms isolated sensitive to ciprofloxacin) and successful (clinical and bacteriological cure of peritonitis) in 62 (83%) of the 75 episodes. The mean ciprofloxacin concentrations in serum and effluent were 1.1 mg/l (range 0-2.9 mg/l) and 10.0 mg/l (range 0.2-33.4 mg/l), respectively, with no evidence of accumulation. Side effects were seen in two patients only, and were mild and transitory.
在一项开放、非对照试验中，对环丙沙星作为治疗持续性非卧床腹膜透析（CAPD）腹膜炎患者经验性治疗的单药疗法进行了评估。44例接受持续性非卧床腹膜透析的患者发生了75次腹膜炎发作并纳入研究。抗生素通过腹腔内给药，每袋透析液中剂量为50mg/L，持续7天。在75次发作中，62次（83%）使用环丙沙星治疗是合适的（分离出的微生物对环丙沙星敏感）且成功（腹膜炎临床和细菌学治愈）。血清和流出液中环丙沙星的平均浓度分别为1.1mg/L（范围0 - 2.9mg/L）和10.0mg/L（范围0.2 - 33.4mg/L），没有蓄积迹象。仅2例患者出现副作用，且症状轻微且短暂。
